ICU Medical Quarterly Filing Shows Mixed Quarter and Softer Six-Month Base While Profitability Holds

Bottom line

- For the three-month reporting period, the company posted lower profit at the parent line and a smaller diluted earnings-per-share result than in the prior-year quarter, while revenue moved higher and operating income improved; this combination is unusual because the top line and operating line strengthened but the bottom line weakened. - For the six-month year-to-date period, the picture shifts: the company grew profit at the operating line and lifted diluted earnings per share, yet revenue contracted against the prior-year period.

The combined three-month and six-month pattern reads as a quarter of weaker parent-level conversion on stronger sales, sitting inside a six-month stretch of improved profitability on a smaller revenue base. - Two revenue series are visible in the cited evidence. The "Revenue from Contract with Customer, Excluding Assessed Tax" line and the "Revenues" line each move in opposite directions when comparing the three-month result against the prior-year quarter (higher) and the six-month result against the prior-year period (lower).

Readers should treat the two labels as separate presentations of the same underlying top-line activity, not as additive figures. - Operating profit for the three-month reporting period is higher than the prior-year quarter, and operating profit for the six-month year-to-date period is also higher than the prior-year period, in both cases a profit-to-profit transition; the gap between the operating line strengthening and the parent line weakening in the quarter therefore sits below operating income. - The earnings-per-share direction differs by window: lower for the three-month comparison against the prior-year quarter (profit to profit) and higher for the six-month comparison against the prior-year period (profit to profit), reinforcing the uneven read between the two reporting windows.

- Source scope is limited to the cited quarterly filing: the 10-Q filed by ICU MEDICAL INC/DE (ICUI, CIK 0000883984, accession 0000883984-26-000041) for the period-ended-2026-06-30. The forward-looking statements section, the risk-factor cross-references in Item 1A, and the segment context in Note 6 define the boundaries of what this filing supports; no peer, industry, or third-party dataset has been used in this section. - The filing evidence does not attribute this change to any single cause.

- The filing evidence contains no peer or industry comparison.

Financial performance

- Reported earnings lines are framed below using both the three-month reporting period and the six-month year-to-date period, with prior-period comparatives drawn from the same windows in the prior year. - Revenue from Contract with Customer, Excluding Assessed Tax was $551,683,000 USD for the three months ended June 30, 2026 versus $548,866,000 USD for the three months ended June 30, 2025, and was $1,081,908,000 USD for the six months ended June 30, 2026 versus $1,153,568,000 USD for the six months ended June 30, 2025. The Revenues line item, presented separately in the consolidated statements, was $551,683,000 USD for the three months ended June 30, 2026 versus $548,866,000 USD for the three months ended June 30, 2025, and $1,081,908,000 USD for the six months ended June 30, 2026 versus $1,153,568,000 USD for the six months ended June 30, 2025. - Operating Income (Loss) was $39,127,000 USD for the three months ended June 30, 2026 versus $10,587,000 USD for the three months ended June 30, 2025, and $52,706,000 USD for the six months ended June 30, 2026 versus $23,475,000 USD for the six months ended June 30, 2025. - Net Income (Loss) Attributable to Parent was $19,087,000 USD for the three months ended June 30, 2026 versus $35,338,000 USD for the three months ended June 30, 2025. - Earnings Per Share, Diluted was $0.76 per diluted share USD/SHARES for the three months ended June 30, 2026 versus $1.43 per diluted share USD/SHARES for the three months ended June 30, 2025, and $1.96 per diluted share USD/SHARES for the six months ended June 30, 2026 versus $0.8 per diluted share USD/SHARES for the six months ended June 30, 2025.

YOY: - The authorized year-over-year picture for the three-month reporting period is mixed: Revenue from Contract with Customer, Excluding Assessed Tax is higher than the prior year and Operating Income (Loss) is higher than the prior year, both remaining in profit, while Revenues is also higher than the prior year. Against that, Earnings Per Share, Diluted is lower than the prior year and Net Income (Loss) Attributable to Parent is lower than the prior year, both remaining in profit. - For the six-month year-to-date period, the authorized year-over-year picture is more uniformly negative: Earnings Per Share, Diluted is higher than the prior year while remaining in profit, and Operating Income (Loss) is higher than the prior year while remaining in profit; but Revenue from Contract with Customer, Excluding Assessed Tax is lower than the prior year and Revenues is lower than the prior year, each remaining positive. - The filing evidence does not attribute this change to any single cause. - Management commentary included in the filing notes certain reclassifications. In the cited note covering Prepaid Expenses and Other Current Assets, amounts previously included in the "other" line item were reclassified to separately present VAT/GST receivables, and prepaid insurance and property taxes and interest rate contracts were combined with the "other" line item. In the cited note covering Segment Data, prior-period significant segment expense amounts were reclassified to conform to the current-year presentation of standard cost of goods sold, other cost of goods sold, and tariffs and duties expense. - The cited note on Basis of Presentation confirms the interim statements were prepared in accordance with U.S. GAAP and SEC rules, reflecting only normal recurring adjustments, and that prior-year amounts have been reclassified to conform to the current-year presentation. - The cited note on New Accounting Pronouncements describes a recently issued ASU covering disclosure improvements in response to the SEC's Disclosure Update and Simplification Initiative, which would require disclosure of disaggregated income statement expense information for specific categories; the guidance is not yet effective for this filing and the Company states it is currently assessing the impact. - Counter-evidence and unknowns: The filing evidence contains no peer or industry comparison. The filing does not provide peer or industry comparison figures, and management does not attribute any of the quarter or year-to-date moves to a single cause. - Readers comparing patterns across issuers can also review Acorn Energy, Inc. Reports Broad Year-Over-Year Decline Across Every Earnings Line Yet Preserves Profitability on a Lower Base for a comparable broad-decline frame.

QOQ: - The filing evidence for this section provides the three-month and six-month windows together with their prior-year comparatives, and does not present a separate sequential (quarter-to-prior-quarter) baseline, so a sequential comparison is not asserted.

GUIDANCE EXPECTATIONS: - The filing's forward-looking-statements language cautions that forward-looking statements are inherently subject to risks and uncertainties, that actual results could differ materially, and that the Company does not plan to publicly update or revise such statements except as required by applicable law. No numerical guidance, outlook range, or forward target is supplied in the cited evidence for this section.

Operating drivers and segments

- Reported segment data is captured in the cited note, where the prior-period significant segment expense table was reclassified to conform to the current-year presentation of standard cost of goods sold, other cost of goods sold, and tariffs and duties expense; readers comparing the two periods should keep that reclassification in mind when reading the segment expense lines. - Revenue from Contract with Customer, Excluding Assessed Tax for the three months ended June 30, 2026 was $551,683,000, higher than the prior-year comparative figure of $548,866,000 for the three months ended June 30, 2025.

- Revenue from Contract with Customer, Excluding Assessed Tax for the six months ended June 30, 2026 was $1,081,908,000, lower than the prior-year comparative figure of $1,153,568,000 for the six months ended June 30, 2025. - A second revenue line, Revenues, is also disclosed: the the three months ended June 30, 2026 figure of $551,683,000 is higher than the prior-year the three months ended June 30, 2025 figure of $548,866,000, while the the six months ended June 30, 2026 figure of $1,081,908,000 is lower than the prior-year the six months ended June 30, 2025 figure of $1,153,568,000.

- Operating Income (Loss) for the three months ended June 30, 2026 was $39,127,000, higher than the prior-year the three months ended June 30, 2025 figure of $10,587,000. - Operating Income (Loss) for the six months ended June 30, 2026 was $52,706,000, higher than the prior-year the six months ended June 30, 2025 figure of $23,475,000. - The contrast between higher quarterly revenue and lower six-month-to-date revenue, alongside higher operating income in both windows, frames the segment-margin discussion without further arithmetic on this page.

- Forward-looking commentary in the filing flags several expected drivers, including expected decreases in restructuring costs, anticipated benefits and costs associated with the OPF purchase agreement, expected capital expenditures, supply chain constraints, the timing and resolution of a Warning Letter, the impact of macroeconomic developments such as foreign exchange, inflation, interest rates, and new accounting and tax regulations, tariffs and the timing of any potential future refunds, and the impact of the OBBBA.

S. trade and tariff policy changes affecting Mexico and Costa Rica, healthcare cost pressure, FDA Warning Letter exposure related to specific infusion pumps, cybersecurity exposure, manufacturing and supply-chain disruption, single and limited-source supplier dependence, restructuring execution risk, distributor concentration, international operations, data privacy and fraud-and-abuse compliance, patent defence, and the integration burden tied to the Smiths Medical acquisition along with the related use of cash and incurrence of debt.

- The cited note carries a reclassification of prior-period segment expenses to align with the current presentation of standard cost of goods sold, other cost of goods sold, and tariffs and duties expense, which is a presentational rather than substantive restatement. - Counter-evidence is limited: the filing evidence does not attribute the reported revenue or operating income changes to any single cause, so the operating-driver picture rests on management's own forward-looking list rather than independent reconciliation.

- For broader context, the year-over-year pattern of a higher quarterly print against a lower six-month-to-date print is not unusual in earnings cycles and can be explored further through pieces such as Acorn Energy, Inc. Reports Broad Year-Over-Year Decline Across Every Earnings Line Yet Preserves Profitability on a Lower Base. - The filing evidence does not attribute this change to any single cause.

- The filing evidence contains no peer or industry comparison.

Cash flow and capital

- Operating cash flow for the six-month year-to-date window the six months ended June 30, 2026 came in positive ($119,059,000), an authorized year-over-year increase versus the prior comparative period the six months ended June 30, 2025 ($62,538,000), which was also positive. The half-year cash-from-operations print is the largest single contributor among the three cash-flow categories. - Investing cash flow flipped sign on a year-over-year basis: the prior-period the six months ended June 30, 2025 reported a positive $170,648,000, while the current the six months ended June 30, 2026 reported a negative -$31,346,000, the authorized decrease driven by that sign transition.

Capital expenditures ($29,813,000) shrank versus the prior-year $34,317,000, the authorized year-over-year decrease for Payments to Acquire Property, Plant, and Equipment, leaving more of the investing outflow to be explained by other investment-activity items rather than by the PP&E line itself. - Financing cash flow remained negative in both periods: -$94,357,000 versus -$251,351,000, the authorized year-over-year increase (smaller use of cash) consistent with debt paydown, lease activity, and equity-related movements in the cited six-month periods.

- On the balance-sheet snapshot at the balance sheet date of June 30, 2026, current Accounts Payable ($149,165,000) and current Accounts Receivable net of allowance ($183,531,000) are reported alongside Long-term Debt excluding current maturities ($1,212,449,000). No working-capital ratios or leverage multiples can be derived here, so the catalog values stand as stated facts without further direction or cause commentary. - A relevant cross-issuer comparison is provided by [Acorn Energy, Inc.

Reports Broad Year-Over-Year Decline Across Every Earnings Line Yet Preserves Profitability on a Lower Base](/insights/finance/acorn-energy-inc-reports-broad-year-over-year-decline-across-every-earnings/), useful here only as context on how mixed year-over-year cash-flow sign patterns can still sit alongside positive profitability. - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

Peer and historical context

- Reported facts, drawn from the filing's primary statements: - Revenue from Contract with Customer, Excluding Assessed Tax was $548,866,000 USD for the three months ended June 30, 2025 and $551,683,000 USD for the three months ended June 30, 2026, moving higher on a year-over-year basis at the quarterly level. - The same revenue line was $1,153,568,000 USD for the six months ended June 30, 2025 and $1,081,908,000 USD for the six months ended June 30, 2026, moving lower on a year-over-year basis at the six-month year-to-date level.

- Revenues, presented as a separate total, was $548,866,000 USD for the three months ended June 30, 2025 and $551,683,000 USD for the three months ended June 30, 2026, also higher year over year at the quarterly level, while the six-month comparison was $1,153,568,000 USD for the six months ended June 30, 2025 and $1,081,908,000 USD for the six months ended June 30, 2026, lower year over year at the year-to-date level. - Operating Income (Loss) was $10,587,000 USD for the three months ended June 30, 2025 and $39,127,000 USD for the three months ended June 30, 2026, higher year over year at the quarterly level, and $23,475,000 USD for the six months ended June 30, 2025 and $52,706,000 USD for the six months ended June 30, 2026, also higher year over year at the six-month level.

Both comparatives remain profitable. - Net Income (Loss) Attributable to Parent was $35,338,000 USD for the three months ended June 30, 2025 and $19,087,000 USD for the three months ended June 30, 2026, lower year over year at the quarterly level while remaining profitable in both periods. - Net Cash Provided by (Used in) Operating Activities was $62,538,000 USD for the six months ended June 30, 2025 and $119,059,000 USD for the six months ended June 30, 2026, higher year over year at the six-month level, with both periods remaining positive.

- Pattern observed across the filing-period versus prior-year comparisons: the quarterly window shows higher revenue on both reported revenue lines and higher operating income, while parent-level net income is lower. The six-month window shows lower revenue on both reported lines but higher operating income and higher operating cash flow. The directional split between the three-month and six-month windows is the most consistent cross-line signal in the reported facts.

- Management explanations carried in the filing: Note 3 discusses Restructuring, Strategic Transaction and Integration charges, mentions an equity-method interest retained after the second-quarter sale of a controlling ownership interest in the IV Solutions business, references fair-value treatment of the retained interest, and describes transition service agreements with an unfavorable contract liability being released to the statements of operations. The filing also describes a pending accounting update whose effective date falls after the current reporting window.

- Analyst inference: Because the three-month window shows higher revenue alongside lower parent-level net income, while the six-month window shows lower revenue but higher operating income and operating cash flow, the quarter-versus-year-to-date gap suggests that items outside the operating line — items discussed in the cited restructuring and integration note — are influencing the relationship between top-line growth and bottom-line results. The cross-period pattern is consistent with a period in which the operating core expanded while discrete items weighed on net income, but the filing does not isolate a single driver.

- Counter-evidence: The reported revenue lines for the six-month period are lower year over year, which runs against the higher operating income and operating cash flow in the same window. Without disclosed segment-level attribution, the headline revenue decline and the operating-income improvement cannot be reconciled to a single segment mix or pricing story. - Notable open questions: The filing does not present a peer-group benchmark, so any read across to other medical-device or infusion-specialty issuers — for example, a comparison framed against [Acorn Energy, Inc.

Reports Broad Year-Over-Year Decline Across Every Earnings Line Yet Preserves Profitability on a Lower Base](/insights/finance/acorn-energy-inc-reports-broad-year-over-year-decline-across-every-earnings/) — would rely on outside data not contained in this filing. The filing evidence does not attribute this change to any single cause. - Unknowns explicitly: The filing evidence contains no peer or industry comparison.

The filing evidence does not disclose segment-level detail for this dimension.

Scenario analysis

- Reported facts that anchor the base case for ICU MEDICAL INC/DE (ICUI) on the period-ended-2026-06-30 form filed at 0000883984-26-000041 under 0000883984: the three-month revenue line is higher than the prior-year quarter, the six-month revenue line is lower than the prior-year half year, and the quarterly net income attributable to parent is lower than the prior-year quarter but still a profit. - Reported values to anchor: $551,683,000 versus $548,866,000 (higher year-over-year); $1,081,908,000 versus $1,153,568,000 (lower year-over-year); $19,087,000 versus $35,338,000 (lower year-over-year, still a profit). - The base case sits squarely on those readings: more revenue in the latest three-month window than a year ago, a softer half-year top line than the comparable prior stretch, and quarterly bottom-line profit that has narrowed but remains positive.

- Reported facts that would tilt the path higher: the three-month revenue gain captured by $551,683,000 versus $548,866,000 (higher) holds into the next quarter, and the six-month revenue shortfall captured by $1,081,908,000 versus $1,153,568,000 (lower) reverses direction in the back half of the year. - Operating income for the three-month and six-month windows is reported as higher than the prior-year periods and remains a profit in both, so the operating line continues to flex in a favorable direction across both windows in the upside read. - Management framing inside the cited note — divesting a controlling stake in the IV Solutions business, retaining an ownership interest, booking cash proceeds, layering in transition service agreements, and releasing an unfavorable contract liability over a multi-year horizon — sets the operating mechanics the upside path runs through.

- Reported facts that would tilt the path lower: the six-month revenue shortfall captured by $1,081,908,000 versus $1,153,568,000 (lower) extends into the back half, and the quarterly profit compression captured by $19,087,000 versus $35,338,000 (lower, still profit) deepens. - Net cash provided by operating activities for the six-month window is higher than the prior-year window, and payments to acquire property, plant, and equipment are lower than the prior-year window; the downside read also pressures reinvestment flexibility, since a softer top line meets a higher operating cash use alongside ongoing capital spending. - The IV Solutions transaction mechanics inside the cited note — service fees, reimbursements, and the unfavorable contract liability release — all flow through cost of goods sold or selling, general and administrative expenses, so a softer contribution from those items on top of an already softer half-year top line is the most direct downside read. - The filing evidence does not attribute this change to any single cause. - For broader context on how three-month-versus-six-month divergence can play out across an earnings cycle, see Atlantic Union Bankshares posts higher year-over-year profit on every reported earnings line for both the three-month reporting period and the six-month year-to-date period.

LINKS: /insights/finance/atlantic-union-bankshares-posts-higher-year-over-year-profit-on-every-reported/

Risks and what to watch

The split picture between the quarter and the half-year window is the central tension going into the next print. For the three-month reporting period, ICU MEDICAL INC/DE's parent-level earnings moved in a direction that the filing authorises as a decrease year over year, with Net Income (Loss) Attributable to Parent falling from $35,338,000 USD in the three months ended June 30, 2025 to $19,087,000 USD in the three months ended June 30, 2026, while still preserving a profit. Revenue from Contract with Customer, Excluding Assessed Tax, however, moved the other way for the same three-month window, climbing from $548,866,000 USD in the three months ended June 30, 2025 to $551,683,000 USD in the three months ended June 30, 2026; the parallel Revenues comparison runs from $548,866,000 USD to $551,683,000 USD. A reader should not interpret that quarter-level revenue gain as confirmation of margin recovery until the next period confirms it.

At the six-month level the picture softens. Revenue from Contract with Customer, Excluding Assessed Tax is reported as lower year over year, sliding from $1,153,568,000 USD in the six months ended June 30, 2025 to $1,081,908,000 USD in the six months ended June 30, 2026, with the parallel Revenues comparison following the same authorised direction from $1,153,568,000 USD to $1,081,908,000 USD. The operating-income line at the six-month level extends an authorised increase, while the parent-level earnings line at the quarter level shows the authorised decrease. The filing evidence does not attribute this change to any single cause.

On the balance-sheet side, the narrative around transition service agreements, a retained ownership interest, and call/put options tied to certain specified dates remains an open consideration for subsequent periods. The cited note describes how an unfavorable contract liability is being released over five years and how the option features do not meet the definition of a derivative because of the absence of a net settlement feature; these structural items are exactly the kind of tail that can re-emerge in future cash or expense lines.

Unknowns worth flagging: the filing carries no peer or industry comparison, so any cross-company read has to be built externally, and the cited note does not provide segment-level breakouts for the quarter. The interaction between the quarter's revenue rise and the parent-level earnings decline is therefore left unexplained here.

- Direction of parent profitability in the next three-month window against the prior-year comparable. - Whether the six-month revenue softness persists, stabilises, or reverses. - Cash-flow trajectory across operating, investing and financing activities relative to the prior-year comparative. - Any movement in the retained-ownership and option mechanics described in Note 3.

Metrics to track include the parent-level earnings line itself, ICUI's revenue line for both the consolidated and contract-with-customer presentations, operating income, and operating cash flow. For a cross-check on how other mid-cap names have handled similar divergence between a softer six-month base and a quarterly recovery, the Acorn Energy, Inc. report on broad year-over-year decline alongside preserved profitability provides a comparable recent template.